These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 12018630)
1. Renal cortical thickness and PON1 activity both decrease in chronic renal failure. Ak G; Ozgönül M; Sözmen EY; Aslan SL; Sözmen B J Nephrol; 2002; 15(2):144-9. PubMed ID: 12018630 [TBL] [Abstract][Full Text] [Related]
2. Plasma paraoxonase-1, oxidized low-density lipoprotein and lipid peroxidation levels in gout patients. Jiang XL; Li M; Zhou JG; Yang QB; Du LJ; Du J Cell Biochem Biophys; 2011 Nov; 61(2):461-6. PubMed ID: 21748243 [TBL] [Abstract][Full Text] [Related]
3. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Saeed SA; Elsharkawy M; Elsaeed K; Fooda O Hemodial Int; 2008 Oct; 12(4):471-9. PubMed ID: 19090870 [TBL] [Abstract][Full Text] [Related]
4. Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease. Göçmen AY; Gümüşlü S; Semiz E Clin Cardiol; 2004 Jul; 27(7):426-30. PubMed ID: 15298047 [TBL] [Abstract][Full Text] [Related]
5. Low high-density lipoprotein cholesterol is not responsible for decreased paraoxonase activity in chronic renal failure. Varga É; Seres I; Harangi M; Kárpáti I; Koncsos P; Sztanek F; Paragh G Kidney Blood Press Res; 2012; 35(4):265-72. PubMed ID: 22378349 [TBL] [Abstract][Full Text] [Related]
6. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks. Sumegová K; Blazícek P; Waczulíková I; Zitnanová I; Duracková Z Acta Biochim Pol; 2006; 53(4):783-7. PubMed ID: 17106515 [TBL] [Abstract][Full Text] [Related]
7. Paraoxonase activity in healthy, diabetic, and hemodialysis patients. Gbandjaba NY; Ghalim N; Hassar M; Berrougui H; Labrazi H; Taki H; Saile R; Khalil A Clin Biochem; 2012 Apr; 45(6):470-4. PubMed ID: 22285382 [TBL] [Abstract][Full Text] [Related]
8. Hypochlorous acid and low serum paraoxonase activity in haemodialysis patients: an in vitro study. Sutherland WH; de Jong SA; Walker RJ Nephrol Dial Transplant; 2004 Jan; 19(1):75-82. PubMed ID: 14671042 [TBL] [Abstract][Full Text] [Related]
9. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. Dirican M; Akca R; Sarandol E; Dilek K J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056 [TBL] [Abstract][Full Text] [Related]
10. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease. Kalogerakis G; Baker AM; Christov S; Rowley KG; Dwyer K; Winterbourn C; Best JD; Jenkins AJ Clin Sci (Lond); 2005 Jun; 108(6):497-506. PubMed ID: 15634192 [TBL] [Abstract][Full Text] [Related]
11. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Liberopoulos EN; Papavasiliou E; Miltiadous GA; Cariolou M; Siamopoulos KC; Tselepis AD; Elisaf MS Perit Dial Int; 2004; 24(6):580-9. PubMed ID: 15559488 [TBL] [Abstract][Full Text] [Related]
12. Serum paraoxonase phenotype distribution in exudative age-related macular degeneration and its relationship to homocysteine and oxidized low-density lipoprotein. Javadzadeh A; Ghorbanihaghjo A; Bahreini E; Rashtchizadeh N; Argani H; Alizadeh S Retina; 2012 Apr; 32(4):658-66. PubMed ID: 22030834 [TBL] [Abstract][Full Text] [Related]
13. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia. Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148 [TBL] [Abstract][Full Text] [Related]
14. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease. Atamer A; Kocyigit Y; Ecder SA; Selek S; Ilhan N; Ecder T; Atamer Y J Nephrol; 2008; 21(6):924-30. PubMed ID: 19034878 [TBL] [Abstract][Full Text] [Related]
15. Effects of estrogen-only therapy on LDL oxidation in women with hysterectomy: does paraoxonase genotype play a role? Akçay YD; Sagin FG; Sendağ F; Oztekin K; Sozmen EY Maturitas; 2006 Feb; 53(3):325-32. PubMed ID: 16023312 [TBL] [Abstract][Full Text] [Related]
16. Antioxidant enzymes and paraoxonase show a co-activity in preserving low-density lipoprotein from oxidation. Sözmen EY; Sözmen B; Girgin FK; Delen Y; Azarsiz E; Erdener D; Ersöz B Clin Exp Med; 2001 Dec; 1(4):195-9. PubMed ID: 11918278 [TBL] [Abstract][Full Text] [Related]
17. PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis. Quéméneur T; Martin-Nizard F; Kandoussi A; Kyndt X; Vanhille P; Hachulla E; Hatron PY; Fruchart JC; Duriez P; Lambert M Semin Arthritis Rheum; 2007 Dec; 37(3):149-55. PubMed ID: 17512573 [TBL] [Abstract][Full Text] [Related]
18. PON1 activity is inversely related to LDL apoB carbonyl content in patients with coronary artery disease. Sharma R; Singh B; Mahajan M Kaohsiung J Med Sci; 2007 May; 23(5):225-31. PubMed ID: 17525004 [TBL] [Abstract][Full Text] [Related]
19. Effects of peritoneal-and hemodialysis on levels of plasma protein and lipid oxidation markers in diabetic patients. Sozer V; Korkmaz Guntas G; Konukoglu D; Dervisoglu E; Gelisgen R; Tabak O; Kalender B; Uzun H Minerva Med; 2013 Feb; 104(1):75-84. PubMed ID: 23392540 [TBL] [Abstract][Full Text] [Related]
20. R/R genotype of human paraoxonase (PON1) is more protective against lipoprotein oxidation and coronary artery disease in Japanese subjects. Kuremoto K; Watanabe Y; Ohmura H; Shimada K; Mokuno H; Daida H J Atheroscler Thromb; 2003; 10(2):85-92. PubMed ID: 12740482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]